NCCN Guidelines Insights: Non–Small Cell Lung Cancer, Version 1.2020

Featured Updates to the NCCN Guidelines

Authors:
David S. Ettinger The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins;

Search for other papers by David S. Ettinger in
Current site
Google Scholar
PubMed Close
 MD
,
Douglas E. Wood University of Washington/Seattle Cancer Care Alliance;

Search for other papers by Douglas E. Wood in
Current site
Google Scholar
PubMed Close
 MD
,
Charu Aggarwal Abramson Cancer Center at the University of Pennsylvania;

Search for other papers by Charu Aggarwal in
Current site
Google Scholar
PubMed Close
 MD, MPH
,
Dara L. Aisner University of Colorado Cancer Center;

Search for other papers by Dara L. Aisner in
Current site
Google Scholar
PubMed Close
 MD, PhD
,
Wallace Akerley Huntsman Cancer Institute at the University of Utah;

Search for other papers by Wallace Akerley in
Current site
Google Scholar
PubMed Close
 MD
,
Jessica R. Bauman Fox Chase Cancer Center;

Search for other papers by Jessica R. Bauman in
Current site
Google Scholar
PubMed Close
 MD
,
Ankit Bharat Robert H. Lurie Comprehensive Cancer Center of Northwestern University;

Search for other papers by Ankit Bharat in
Current site
Google Scholar
PubMed Close
 MD
,
Debora S. Bruno Case Comprehensive Cancer Center/University Hospitals Seidman Cancer Center and Cleveland Clinic Taussig Cancer Institute;

Search for other papers by Debora S. Bruno in
Current site
Google Scholar
PubMed Close
 MD, MS
,
Joe Y. Chang The University of Texas MD Anderson Cancer Center;

Search for other papers by Joe Y. Chang in
Current site
Google Scholar
PubMed Close
 MD, PhD
,
Lucian R. Chirieac Dana-Farber/Brigham and Women’s Cancer Center;

Search for other papers by Lucian R. Chirieac in
Current site
Google Scholar
PubMed Close
 MD
,
Thomas A. D’Amico Duke Cancer Institute;

Search for other papers by Thomas A. D’Amico in
Current site
Google Scholar
PubMed Close
 MD
,
Thomas J. Dilling Moffitt Cancer Center;

Search for other papers by Thomas J. Dilling in
Current site
Google Scholar
PubMed Close
 MD, MS
,
Michael Dobelbower O’Neal Comprehensive Cancer Center at UAB;

Search for other papers by Michael Dobelbower in
Current site
Google Scholar
PubMed Close
 MD, PhD
,
Scott Gettinger Yale Cancer Center/Smilow Cancer Hospital;

Search for other papers by Scott Gettinger in
Current site
Google Scholar
PubMed Close
 MD
,
Ramaswamy Govindan Siteman Cancer Center at Barnes-Jewish Hospital and Washington University School of Medicine;

Search for other papers by Ramaswamy Govindan in
Current site
Google Scholar
PubMed Close
 MD
,
Matthew A. Gubens UCSF Helen Diller Family Comprehensive Cancer Center;

Search for other papers by Matthew A. Gubens in
Current site
Google Scholar
PubMed Close
 MD, MS
,
Mark Hennon Roswell Park Comprehensive Cancer Institute;

Search for other papers by Mark Hennon in
Current site
Google Scholar
PubMed Close
 MD
,
Leora Horn Vanderbilt-Ingram Cancer Center;

Search for other papers by Leora Horn in
Current site
Google Scholar
PubMed Close
 MD, MSc
,
Rudy P. Lackner Fred & Pamela Buffett Cancer Center;

Search for other papers by Rudy P. Lackner in
Current site
Google Scholar
PubMed Close
 MD
,
Michael Lanuti Massachusetts General Hospital Cancer Center;

Search for other papers by Michael Lanuti in
Current site
Google Scholar
PubMed Close
 MD
,
Ticiana A. Leal University of Wisconsin Carbone Cancer Center;

Search for other papers by Ticiana A. Leal in
Current site
Google Scholar
PubMed Close
 MD
,
Jules Lin University of Michigan Rogel Cancer Center;

Search for other papers by Jules Lin in
Current site
Google Scholar
PubMed Close
 MD
,
Billy W. Loo Jr Stanford Cancer Institute;

Search for other papers by Billy W. Loo Jr in
Current site
Google Scholar
PubMed Close
 MD, PhD
,
Renato G. Martins University of Washington/Seattle Cancer Care Alliance;

Search for other papers by Renato G. Martins in
Current site
Google Scholar
PubMed Close
 MD, MPH
,
Gregory A. Otterson The Ohio State University Comprehensive Cancer Center - James Cancer Hospital and Solove Research Institute;

Search for other papers by Gregory A. Otterson in
Current site
Google Scholar
PubMed Close
 MD
,
Sandip P. Patel UC San Diego Moores Cancer Center;

Search for other papers by Sandip P. Patel in
Current site
Google Scholar
PubMed Close
 MD
,
Karen L. Reckamp City of Hope National Medical Center;

Search for other papers by Karen L. Reckamp in
Current site
Google Scholar
PubMed Close
 MD, MS
,
Gregory J. Riely Memorial Sloan Kettering Cancer Center;

Search for other papers by Gregory J. Riely in
Current site
Google Scholar
PubMed Close
 MD, PhD
,
Steven E. Schild Mayo Clinic Cancer Center;

Search for other papers by Steven E. Schild in
Current site
Google Scholar
PubMed Close
 MD
,
Theresa A. Shapiro The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins;

Search for other papers by Theresa A. Shapiro in
Current site
Google Scholar
PubMed Close
 MD, PhD
,
James Stevenson Case Comprehensive Cancer Center/University Hospitals Seidman Cancer Center and Cleveland Clinic Taussig Cancer Institute;

Search for other papers by James Stevenson in
Current site
Google Scholar
PubMed Close
 MD
,
Scott J. Swanson Dana-Farber/Brigham and Women’s Cancer Center;

Search for other papers by Scott J. Swanson in
Current site
Google Scholar
PubMed Close
 MD
,
Kurt W. Tauer St. Jude Children’s Research Hospital/The University of Tennessee Health Science Center; and

Search for other papers by Kurt W. Tauer in
Current site
Google Scholar
PubMed Close
 MD
,
Stephen C. Yang The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins;

Search for other papers by Stephen C. Yang in
Current site
Google Scholar
PubMed Close
 MD
,
Kristina Gregory
Search for other papers by Kristina Gregory in
Current site
Google Scholar
PubMed Close
 RN, MSN
,
OCN National Comprehensive Cancer Network.

Search for other papers by OCN in
Current site
Google Scholar
PubMed Close
, and
Miranda Hughes National Comprehensive Cancer Network.

Search for other papers by Miranda Hughes in
Current site
Google Scholar
PubMed Close
 PhD
Volume/Issue:
Volume 17: Issue 12
Online Publication Date:
Dec 2019
DOI:
https://doi.org/10.6004/jnccn.2019.0059
Restricted access

The NCCN Guidelines for Non–Small Cell Lung Cancer (NSCLC) address all aspects of management for NSCLC. These NCCN Guidelines Insights focus on recent updates in immunotherapy. For the 2020 update, all of the systemic therapy regimens have been categorized using a new preference stratification system; certain regimens are now recommended as “preferred interventions,” whereas others are categorized as either “other recommended interventions” or “useful under certain circumstances.”

  • Collapse
  • Expand
Print ISSN:
1540-1405
Online ISSN:
1540-1413
Publisher:
National Comprehensive Cancer Network
Cover Journal of the National Comprehensive Cancer Network
  • 1.

    Siegel RL, Miller KD, Jemal A. Cancer statistics, 2019. CA Cancer J Clin 2019;69:7–34.

  • 2.

    Howlader N, Noone AM, Krapcho M, et al.. SEER Cancer Statistics Review, 1975-2016, National Cancer Institute. Bethesda, MD. Available at https://seer.cancer.gov/csr/1975_2016/. Based on November 2018 SEER data submission, posted to the SEER website, April 2019. Accessed October 20, 2019.

    • PubMed
    • Export Citation
  • 3.

    Garon EB, Hellmann MD, Rizvi NA, et al.. Five-year overall survival for patients with advanced non‒small-cell lung cancer treated with pembrolizumab: results from the phase I KEYNOTE-001 study. J Clin Oncol 2019;37:2518–2527.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 4.

    Leighl NB, Hellmann MD, Hui R, et al.. Pembrolizumab in patients with advanced non-small-cell lung cancer (KEYNOTE-001): 3-year results from an open-label, phase 1 study. Lancet Respir Med 2019;7:347–357.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 5.

    Lin JJ, Cardarella S, Lydon CA, et al.. Five-year survival in EGFR-mutant metastatic lung adenocarcinoma treated with EGFR-TKIs. J Thorac Oncol 2016;11:556–565.

  • 6.

    Pacheco JM, Gao D, Smith D, et al.. Natural history and factors associated with overall survival in stage IV ALK-rearranged non-small cell lung cancer. J Thorac Oncol 2019;14:691–700.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 7.

    Shaw AT, Riely GJ, Bang YJ, et al.. Crizotinib in ROS1-rearranged advanced non-small-cell lung cancer (NSCLC): updated results, including overall survival, from PROFILE 1001. Ann Oncol 2019;30:1121–1126.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 8.

    Singhi EK, Horn L, Sequist LV, et al.. Advanced non-small cell lung cancer: sequencing agents in the EGFR-mutated/ALK-rearranged populations. Am Soc Clin Oncol Educ Book 2019;39:e187–197.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 9.

    Zhao D, Chen X, Qin N, et al.. The prognostic role of EGFR-TKIs for patients with advanced non-small cell lung cancer. Sci Rep 2017;7:40374.

  • 10.

    Johung KL, Yeh N, Desai NB, et al.. Extended survival and prognostic factors for patients with ALK-rearranged non-small-cell lung cancer and brain metastasis. J Clin Oncol 2016;34:123–129.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 11.

    Reck M, Rodríguez-Abreu D, Robinson AG, et al.. Updated analysis of KEYNOTE-024: pembrolizumab versus platinum-based chemotherapy for advanced non-small-cell lung cancer with PD-L1 tumor proportion score of 50% or greater. J Clin Oncol 2019;37:537–546.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 12.

    Antonia SJ, Borghaei H, Ramalingam SS, et al.. Four-year survival with nivolumab in patients with previously treated advanced non-small-cell lung cancer: a pooled analysis. Lancet Oncol 2019;20:1395–1408.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 13.

    Drilon A, Laetsch TW, Kummar S, et al.. Efficacy of larotrectinib in TRK fusion-positive cancers in adults and children. N Engl J Med 2018;378:731–739.

  • 14.

    Solomon BJ, Besse B, Bauer TM, et al.. Lorlatinib in patients with ALK-positive non-small-cell lung cancer: results from a global phase 2 study. Lancet Oncol 2018;19:1654–1667.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 15.

    Wu YL, Cheng Y, Zhou X, et al.. Dacomitinib versus gefitinib as first-line treatment for patients with EGFR-mutation-positive non-small-cell lung cancer (ARCHER 1050): a randomised, open-label, phase 3 trial. Lancet Oncol 2017;18:1454–1466.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 16.

    Gandhi L, Rodríguez-Abreu D, Gadgeel S, et al.. Pembrolizumab plus chemotherapy in metastatic non-small-cell lung cancer. N Engl J Med 2018;378:2078–2092.

  • 17.

    Socinski MA, Jotte RM, Cappuzzo F, et al.. Atezolizumab for first-line treatment of metastatic nonsquamous NSCLC. N Engl J Med 2018;378:2288–2301.

  • 18.

    Paz-Ares L, Luft A, Vicente D, et al.. Pembrolizumab plus chemotherapy for squamous non-small-cell lung cancer. N Engl J Med 2018;379:2040–2051.

  • 19.

    Mok TS, Cheng Y, Zhou X, et al.. Improvement in overall survival in a randomized study that compared dacomitinib with gefitinib in patients with advanced non-small-cell lung cancer and EGFR-activating mutations. J Clin Oncol 2018;36:2244–2250.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 20.

    Ettinger DS, Wood DE, Aggarwal C, et al.. NCCN Clinical Practice Guidelines in Oncology: Non-Small Cell Lung Cancer. Version 7.2019. Accessed August 30, 2019. To view the most recent version, visit NCCN.org.

    • PubMed
    • Export Citation
  • 21.

    Reck M, Rodríguez-Abreu D, Robinson AG, et al.. Pembrolizumab versus chemotherapy for PD-L1-positive non-small-cell lung cancer. N Engl J Med 2016;375:1823–1833.

  • 22.

    Mok TSK, Wu YL, Kudaba I, et al.. Pembrolizumab versus chemotherapy for previously untreated, PD-L1-expressing, locally advanced or metastatic non-small-cell lung cancer (KEYNOTE-042): a randomised, open-label, controlled, phase 3 trial. Lancet 2019;393:1819–1830.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 23.

    Lindeman NI, Cagle PT, Aisner DL, et al.. Updated molecular testing guideline for the selection of lung cancer patients for treatment with targeted tyrosine kinase inhibitors: guideline from the College of American Pathologists, the International Association for the Study of Lung Cancer, and the Association for Molecular Pathology. Arch Pathol Lab Med 2018;142:321–346.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 24.

    Soria JC, Ohe Y, Vansteenkiste J, et al.. Osimertinib in untreated EGFR-mutated advanced non-small-cell lung cancer. N Engl J Med 2018;378:113–125.

  • 25.

    Lisberg A, Cummings A, Goldman JW, et al.. A phase II study of pembrolizumab in EGFR-mutant, PD-L1+, tyrosine kinase inhibitor naive patients with advanced NSCLC. J Thorac Oncol 2018;13:1138–1145.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 26.

    Camidge DR, Dziadziuszko R, Peters S, et al.. Updated efficacy and safety data and impact of the EML4-ALK fusion variant on the efficacy of alectinib in untreated ALK-positive advanced non-small cell lung cancer in the global phase III ALEX study. J Thorac Oncol 2019;14:1233–1243.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 27.

    Garassino M, Rodriguez-Abreu D, Gadgeel S, et al.. Evaluation of TMB in KEYNOTE-189: pembrolizumab plus chemotherapy vs placebo plus chemotherapy for nonsquamous NSCLC [abstract]. J Thorac Oncol 2019;14:S216–217. Abstract OA04.06.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 28.

    Reck M, Mok TSK, Nishio M, et al.. Atezolizumab plus bevacizumab and chemotherapy in non-small-cell lung cancer (IMpower150): key subgroup analyses of patients with EGFR mutations or baseline liver metastases in a randomised, open-label phase 3 trial. Lancet Respir Med 2019;7:387–401.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 29.

    Langer CJ, Gadgeel SM, Borghaei H, et al.. Carboplatin and pemetrexed with or without pembrolizumab for advanced, non-squamous non-small-cell lung cancer: a randomised, phase 2 cohort of the open-label KEYNOTE-021 study. Lancet Oncol 2016;17:1497–1508.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 30.

    Thatcher N, Goldschmidt JH, Thomas M, et al.. Efficacy and safety of the biosimilar ABP 215 compared with bevacizumab in patients with advanced nonsquamous non-small cell lung cancer (MAPLE): a randomized, double-blind, phase III study. Clin Cancer Res 2019;25:2088–2095.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 31.

    Reinmuth N, Bryl M, Bondarenko I, et al.. PF-06439535 (a bevacizumab biosimilar) compared with reference bevacizumab (Avastin), both plus paclitaxel and carboplatin, as first-line treatment of advanced non-squamous non-small-cell lung cancer: a randomized, double-blind study. BioDrugs 2019;33:555–570.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 32.

    Melosky B, Reardon DA, Nixon AB, et al.. Bevacizumab biosimilars: scientific justification for extrapolation of indications. Future Oncol 2018;14:2507–2520.

  • 33.

    Weise M, Kurki P, Wolff-Holz E, et al.. Biosimilars: the science of extrapolation. Blood 2014;124:3191–3196.

  • 34.

    Weise M, Bielsky MC, De Smet K, et al.. Biosimilars: what clinicians should know. Blood 2012;120:5111–5117.

  • 35.

    Paz-Ares LG, Luft A, Tafreshi A, et al.. Phase 3 study of carboplatin-paclitaxel/nab-paclitaxel (Chemo) with or without pembrolizumab for patients with metastatic squamous non-small cell lung cancer [abstract]. J Clin Oncol 2018;36:Abstract 105.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
Copyright:
Copyright © 2019 by the National Comprehensive Cancer Network 2019
Page Numbers:
9
Article Category:
Other
Print Publication Date:
01 Dec 2019
Online Publication Date:
Dec 2019

Metrics

All Time Past Year Past 30 Days
Abstract Views 0 0 0
Full Text Views 44448 4384 408
PDF Downloads 21962 2194 135
EPUB Downloads 0 0 0